Try our mobile app

Switch to company model in "Rising Stars" logic    *

General information

Country: UNITED STATES

Sector: Diagnostics and Research

CareDx, Inc. develops, markets, and delivers a diagnostic surveillance solution for heart transplant recipients. The Company aims to transform long-term patient care in transplantation by offering novel surveillance management solutions.
Website: caredx.com


  • Bad financial results growth rate -37.3% (average between last period year over year growth for revenue and EBITDA), there is slowdown compared to average historical growth rates (20.2%)
  • Dividend yield for the last twelve months 0.0%
  • Free cash flow yield -7.1% (LTM)
  • Share price is 350.4% higher than minimum and 35.1% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (500.0x vs 14.7x)
  • For the last 3 months insiders sold company shares on $0.5 mln (-0.046% of cap.)

Key Financials (Download financials)

Ticker: CDNA
Share price, USD:  (-3.2%)22.07
year average price 17.99  


year start price 19.30 2025-06-04

min close price 11.57 2025-08-19

max close price 22.82 2026-05-29

current price 22.07 2026-06-03
Common stocks: 51 124 846

Dividend Yield:  0.0%
EV / Sales: 2.6x
Margin (EBITDA LTM / Revenue): -6.1%

Target EV / EBITDA (hist percentile): 14.7x
Express share price potential:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 1 128
Net Debt ($m): -158
EV (Enterprise Value): 970
EBITDA LTM (млн $): -23
Price to Book: 3.6x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2026-02-01fool.com

CareDx's CEO Conducts Multiple Sale of Shares Towards the End of January 2026

2026-01-12businesswire.com

CareDx Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results

2025-12-26businesswire.com

CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2025-11-27zacks.com

Wall Street Analysts Believe CareDx (CDNA) Could Rally 28.02%: Here's is How to Trade

2025-11-04seekingalpha.com

CareDx, Inc (CDNA) Q3 2025 Earnings Call Transcript

2025-11-04zacks.com

CareDx (CDNA) Surpasses Q3 Earnings and Revenue Estimates

2025-10-27businesswire.com

CareDx Announces Appointment of Jeffrey John Teuteberg, MD as Chief Medical Officer

2025-10-06businesswire.com

CareDx Announces New IVD Products and IVDR Certification for AlloSeq® Tx and QTYPE® at the 2025 American Society of Histocompatibility & Immunogenetics Annual Meeting

2025-08-06seekingalpha.com

CareDx, Inc (CDNA) Q2 2025 Earnings Call Transcript

2025-08-06zacks.com

CareDx (CDNA) Lags Q2 Earnings and Revenue Estimates
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol CDNA CDNA CDNA CDNA CDNA CDNA CDNA CDNA CDNA CDNA CDNA CDNA CDNA CDNA
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-04 2025-08-06 2024-11-04 2024-07-31 2024-05-09 2023-11-08 2023-08-08 2023-05-10 2022-11-03
acceptedDate 2025-11-04 16:13:11 2025-08-06 16:11:48 2025-02-27 17:49:04 2024-11-04 16:18:08 2024-07-31 16:16:12 2024-05-09 16:14:55 2023-12-30 19:00:00 2023-11-08 16:16:37 2023-08-08 16:18:07 2023-05-10 16:20:16 2023-02-27 16:28:48 2022-11-03 16:23:36 2022-02-24 17:07:19 2021-02-24 17:03:10
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 100M 87M 334M 83M 92M 72M 280M 67M 70M 77M 322M 79M 296M 192M
costOfRevenue 31M 29M 110M 28M 29M 27M 102M 25M 26M 26M 112M 28M 97M 63M
grossProfit 69M 58M 224M 55M 64M 45M 178M 43M 44M 51M 210M 51M 199M 129M
grossProfitRatio 0.687 0.669 0.667 0.69 0.631 0.635 0.632 0.664 0.643
researchAndDevelopmentExpenses 17M 17M 72M 17M 20M 19M 82M 19M 20M 24M 90M 22M 77M 49M
generalAndAdministrativeExpenses 28M 28M 124M 29M 28M 27M 118M 34M 29M 28M 100M 24M 75M 49M
sellingAndMarketingExpenses 24M 24M 82M 20M 21M 20M 83M 18M 22M 23M 96M 22M 77M 54M
sellingGeneralAndAdministrativeExpenses 53M 52M 206M 48M 48M 46M 201M 52M 51M 51M 196M 46M 152M 103M
otherExpenses -3M 350 000 -95M 0 -100 000 -290 000 99M 2M -271 000 -2M 0 0 0 0
operatingExpenses 67M 69M 183M 66M 68M 65M 382M 71M 71M 76M 287M 68M 229M 152M
costAndExpenses 98M 98M 293M 93M 96M 91M 484M 96M 97M 102M 399M 97M 326M 215M
interestIncome 2M 2M 12M 3M 3M 3M 12M 3M 3M 3M 4M 1M 160 000 271 000
interestExpense 0 0 0 0 0 0 0 0 0 -451 000 0 1M 0 0
depreciationAndAmortization 5M 5M 20M 5M 5M 5M 20M 5M 5M -7000 16M 4M 12M 10M
ebitda 7M -6M -34M -6M 927 000 -14M -85M -24M -21M -24M -61M -13M -18M -8M
ebitdaratio 0.068 -0.066 -0.068 0.01 -0.196 -0.354 -0.298 -0.315 -0.164
operatingIncome 2M -11M 41M -10M -4M -19M -203M -29M -28M -24M -77M -17M -30M -23M
operatingIncomeRatio 0.02 -0.128 -0.127 -0.044 -0.268 -0.428 -0.393 -0.315 -0.218
totalOtherIncomeExpensesNet -352 000 2M 12M 3M 3M 3M 13M 2M -1M 699 000 997 000 667 000 -2M 3M
incomeBeforeTax 2M -9M 53M -7M -1M -17M -190M -24M -25M -24M -76M -17M -32M -20M
incomeBeforeTaxRatio 0.017 -0.1 -0.087 -0.015 -0.232 -0.351 -0.356 -0.306 -0.21
incomeTaxExpense -15 000 -117 000 310 000 200 000 22 000 -83 000 141 000 -80 000 -68 000 124 000 379 000 267 000 -1M -1M
netIncome 2M -9M 53M -7M -1M -17M -190M -23M -25M -24M -77M -17M -31M -19M
netIncomeRatio 0.017 -0.099 -0.089 -0.015 -0.231 -0.35 -0.355 -0.307 -0.213
eps 0.03 -0.16 1 -0.14 -0.027 -0.32 -3.54 -0.43 -0.46 -0.44 -1.44 -0.32 -0.59 -0.4
epsdiluted 0.03 -0.16 -0.14 -0.027 -0.32 -0.43 -0.46 -0.44 -0.32
weightedAverageShsOut 53M 54M 53M 53M 52M 52M 54M 54M 54M 54M 53M 53M 52M 46M
weightedAverageShsOutDil 54M 54M 57M 53M 52M 52M 54M 54M 54M 54M 53M 53M 52M 46M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-28 2023-12-31 2023-02-27 2022-02-24 2021-02-24
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome 12M 12M 4M 160 000 271 000
ebit -54M -105M -77M -30M -18M
nonOperatingIncomeExcludingInterest 95M -99M 0 0 -5M
netIncomeFromContinuingOperations 53M -190M -77M -31M -19M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome 53M -190M -77M -31M -19M
epsDiluted 0.93 -3.54 -1.44 -0.59 -0.4

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol CDNA CDNA CDNA CDNA CDNA CDNA CDNA CDNA CDNA CDNA CDNA CDNA CDNA CDNA
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-04 2025-08-06 2024-11-04 2024-07-31 2024-05-09 2023-11-08 2023-08-08 2023-05-10 2022-11-03
acceptedDate 2025-11-04 16:13:11 2025-08-06 16:11:48 2025-02-27 17:49:04 2024-11-04 16:18:08 2024-07-31 16:16:12 2024-05-09 16:14:55 2023-12-30 19:00:00 2023-11-08 16:16:37 2023-08-08 16:18:07 2023-05-10 16:20:16 2023-02-27 16:28:48 2022-11-03 16:23:36 2022-02-24 17:07:19 2021-02-24 17:03:10
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 91M 68M 115M 95M 96M 93M 82M 76M 88M 75M 90M 83M 348M 135M
shortTermInvestments 103M 118M 146M 145M 133M 123M 153M 192M 195M 211M 203M 208M 0 90M
cashAndShortTermInvestments 194M 186M 261M 241M 229M 216M 235M 268M 283M 286M 293M 291M 348M 225M
netReceivables 48M 67M 65M 67M 66M 60M 51M 52M 52M 59M 66M 70M 60M 35M
inventory 28M 28M 20M 19M 19M 20M 19M 18M 19M 18M 19M 18M 17M 10M
otherCurrentAssets 30M 26M 7M 7M 6M 7M 8M 7M 8M 8M 9M 8M 0 0
totalCurrentAssets 300M 307M 352M 334M 321M 303M 314M 345M 361M 371M 388M 388M 433M 273M
propertyPlantEquipmentNet 55M 57M 58M 60M 61M 63M 65M 66M 68M 69M 70M 70M 40M 26M
goodwill 40M 40M 40M 40M 40M 40M 40M 40M 40M 40M 38M 38M 37M 24M
intangibleAssets 33M 36M 38M 40M 42M 43M 46M 46M 44M 46M 43M 44M 50M 44M
goodwillAndIntangibleAssets 74M 76M 79M 81M 82M 84M 86M 87M 83M 85M 81M 81M 87M 68M
longTermInvestments 0 0 0 0 588 000 583 000 0 582 000 584 000 0 0 0 0 0
taxAssets 0 0 0 0 0 -1 0 -582 000 -584 000 0 0 0 0 0
otherNonCurrentAssets 3M 3M 3M 2M 2M 2M 2M 3M 3M 3M 4M 5M 6M 1M
totalNonCurrentAssets 132M 137M 139M 143M 146M 149M 153M 156M 154M 157M 155M 156M 133M 95M
otherAssets 0 0 0 0 0 1 0 0 0 0 0 0 0 0
totalAssets 432M 444M 491M 477M 467M 452M 467M 501M 515M 528M 543M 545M 567M 369M
accountPayables 12M 10M 8M 6M 6M 10M 13M 9M 10M 13M 10M 11M 13M 10M
shortTermDebt 6M 6M 0 7M 6M 6M 0 6M 6M 6M 0 5M 0 0
taxPayables 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredRevenue 0 6M 5M 6M 6M 4M 5M 6M 6M 6M 5M 5M 4M 24M
otherCurrentLiabilities 81M 71M 41M 64M 61M 50M 26M 52M 53M 47M 21M 50M 33M 21M
totalCurrentLiabilities 99M 93M 89M 81M 78M 70M 78M 73M 74M 72M 76M 70M 77M 69M
longTermDebt 21M 23M 0 24M 25M 27M 0 29M 31M 32M 0 35M 0 0
deferredRevenueNonCurrent 0 0 0 0 0 -96M 0 5M 4M 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 131 000 164 000 202 000 50 000 43 000 136 000 140 000 51 000 0 0 13 000 415 000 1M
otherNonCurrentLiabilities 911 000 796 000 819 000 98M 98M 195M 99M 245 000 247 000 4M 3M 17M 6M 4M
totalNonCurrentLiabilities 22M 24M 23M 122M 124M 126M 127M 34M 35M 36M 36M 38M 23M 22M
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 28M 29M 28M 30M 31M 27M 34M 35M 36M 32M 39M 40M 21M 18M
totalLiabilities 121M 117M 113M 204M 202M 196M 205M 107M 110M 108M 112M 108M 101M 91M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 51 000 53 000 51 000 50 000 50 000 49 000 49 000 52 000 52 000 52 000 52 000 52 000 52 000 49 000
retainedEarnings -719M -695M -626M -704M -697M -695M -678M -534M -510M -485M -460M -441M -383M -353M
accumulatedOtherComprehensiveIncomeLoss -6M -6M -9M -7M -8M -8M -7M -9M -8M -7M -8M -9M -5M -2M
othertotalStockholdersEquity 1 036M 1 029M 985M 969M 960M 937M 924M 912M 887M
totalStockholdersEquity 311M 327M 378M 273M 265M 256M 261M 394M 405M 420M 431M 437M 466M 278M
totalEquity 311M 327M 378M 273M 265M 256M 261M 394M 405M 420M 431M 437M 466M 278M
totalLiabilitiesAndStockholdersEquity 432M 444M 477M 467M 452M 501M 515M 528M 545M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 432M 444M 491M 477M 467M 452M 467M 501M 515M 528M 543M 545M 567M 369M
totalInvestments 103M 118M 146M 145M 134M 123M 153M 192M 195M 211M 203M 208M 0 90M
totalDebt 28M 29M 28M 30M 31M 33M 34M 35M 36M 32M 39M 40M 21M 18M
netDebt -64M -39M -86M -65M -64M -60M -48M -41M -51M -43M -51M -43M -327M -117M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-28 2023-12-31 2023-02-27 2022-02-24 2021-02-24
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 65M 51M 66M 60M 35M
otherReceivables 0 0 0 0 0
prepaids 0 0 0 8M 4M
totalPayables 8M 13M 10M 13M 10M
otherPayables 0 0 0 0 0
accruedExpenses 30M 28M 34M 23M 12M
capitalLeaseObligationsCurrent 6M 6M 6M 4M 2M
capitalLeaseObligationsNonCurrent 22M 28M 33M 17M 16M
treasuryStock 0 0 0 0 0
additionalPaidInCapital 1 013M 947M 899M 854M 632M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol CDNA CDNA CDNA CDNA CDNA CDNA CDNA CDNA CDNA CDNA CDNA CDNA CDNA CDNA
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-04 2025-08-06 2024-11-04 2024-07-31 2024-05-09 2023-11-08 2023-08-08 2023-05-10 2022-11-03
acceptedDate 2025-11-04 16:13:11 2025-08-06 16:11:48 2025-02-27 17:49:04 2024-11-04 16:18:08 2024-07-31 16:16:12 2024-05-09 16:14:55 2023-12-30 19:00:00 2023-11-08 16:16:37 2023-08-08 16:18:07 2023-05-10 16:20:16 2023-02-27 16:28:48 2022-11-03 16:23:36 2022-02-24 17:07:19 2021-02-24 17:03:10
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome 2M -9M 53M -7M -1M -17M -190M -23M -25M -24M -77M -17M -31M -19M
depreciationAndAmortization 5M 5M 20M 5M 5M 5M 20M 5M 5M 5M 16M 4M 12M 10M
deferredIncomeTax 0 0 -187 000 0 0 -93 000 566 000 -949 000 -1M 0 0 0 0 0
stockBasedCompensation 8M 9M 66M 14M 13M 13M 49M 13M 13M 14M 47M 11M 36M 23M
changeInWorkingCapital 19M 4M -102M 759 000 3M -19M 106M -3M 8M 4M -14M -7M -41M 17M
accountsReceivables 20M 4M -14M -343 000 -6M -9M 16M 126 000 8M 8M -7M -276 000 -24M -10M
inventory -252 000 -4M -1M 519 000 1M -1M 54 000 746 000 -1M 1M -3M 248 000 -7M -3M
accountsPayables 2M 1M -5M 220 999 -4M -3M 3M -1M -3M 3M -2M -6M 2M 4M
otherWorkingCapital -2M 2M -82M 362 001 12M -6M 87M -2M 4M -7M -3M -727 000 -11M 27M
otherNonCashItems 3M 226 000 2M 588 001 32M 39M -4M -866 000 124 000 1M 3M 1M 4M 2M
netCashProvidedByOperatingActivities 37M 10M 38M 13M 19M -15M -18M -10M -499 000 671 000 -25M -7M -19M 33M
investmentsInPropertyPlantAndEquipment -2M -1M 0 3M -2M -1M -9M -3M -2M -3M -24M -6M -20M -10M
acquisitionsNet 0 0 0 0 0 0 -7M -2M 2M -5M -610 000 -508 000 -15M 0
purchasesOfInvestments -17M -15M -160M -50M -35M -58M -201M -58M -49M -86M -315M -101M -6M -90M
salesMaturitiesOfInvestments 31M 39M 167M 37M 26M 87M 256M 61M 67M 79M 112M 31M 89M 0
otherInvestingActivites 0 0 -5M -10M 29M -865 000 -2M 0 0
netCashUsedForInvestingActivites 12M 23M -14M -12M 28M -1M 15M -15M -76M
debtRepayment 0 0 0 0 0 0 0 0 0
commonStockIssued 232 000 0 4M 123 000 540 000 1M 9000 2000 0
commonStockRepurchased -26M -50M -522 000 0 -4M -522 000 -28M -814 000 -67 000 -690 000 -642 000 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites -1M -4M -3M -5M -1M -350 000 -2M -450 000 -1M
netCashUsedProvidedByFinancingActivities -26M -54M 1M -5M -1M -25 000 -2M -1M -1M
effectOfForexChangesOnCash -6000 -13 000 532 000 84 000 15 000 26 000 -112 000 -106 000 -93 000 -25 000 23 000 -34 000 -303 000 274 000
netChangeInCash 23M -21M 32M 210 000 2M 11M -8M -12M 13M -15M -258M -84M 214M 96M
cashAtEndOfPeriod 91M 69M 115M 96M 96M 93M 83M 77M 88M 75M 90M 83M 349M 135M
cashAtBeginningOfPeriod 68M 89M 83M 96M 93M 82M 90M 88M 75M 90M 349M 167M 135M 38M
operatingCashFlow 37M 10M 38M 13M 19M -15M -18M -10M -499 000 671 000 -25M -7M -19M 33M
capitalExpenditure -1M -1M -6M 3M -2M -1M -9M -3M -2M -3M -24M -6M -20M -10M
freeCashFlow 36M 9M 32M 16M 17M -17M -28M -13M -3M -2M -50M -13M -40M 23M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-28 2023-12-31 2023-02-27 2022-02-24 2021-02-24
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities -7M 1M 0 0 0
netCashProvidedByInvestingActivities -483 000 40M -229M 48M -100M
netDebtIssuance 0 0 0 -66 000 -183 000
longTermNetDebtIssuance 0 0 0 -66 000 -183 000
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance -522 000 -28M -642 000 189M 158M
netCommonStockIssuance -522 000 -28M -642 000 189M 158M
commonStockIssuance 0 0 0 189M 158M
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities -5M -2M -4M -3M 5M
netCashProvidedByFinancingActivities -6M -30M -5M 186M 163M
incomeTaxesPaid 317 000 738 000 392 000 14 000 80 000
interestPaid 0 0 8000 1000 10000

Earning call transcript

2025 q3
2025-11-04 ET (fiscal 2025 q3)
2025 q2
2025-08-06 ET (fiscal 2025 q2)
2025 q1
2025-04-30 ET (fiscal 2025 q1)
2024 q4
2025-02-26 ET (fiscal 2024 q4)
2024 q3
2024-11-04 ET (fiscal 2024 q3)
2024 q2
2024-07-31 ET (fiscal 2024 q2)
2024 q1
2024-05-09 ET (fiscal 2024 q1)
2023 q4
2024-02-28 ET (fiscal 2023 q4)
2023 q3
2023-11-08 ET (fiscal 2023 q3)
2023 q2
2023-08-08 ET (fiscal 2023 q2)
2023 q1
2023-05-12 ET (fiscal 2023 q1)
2022 q4
2023-02-27 ET (fiscal 2022 q4)
2022 q3
2022-11-03 ET (fiscal 2022 q3)
2022 q2
2022-08-07 ET (fiscal 2022 q2)
2022 q1
2022-05-05 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2026-04-28 20:05 ET
CareDx Announces Agreement to Acquire Naveris, A Leader in Viral-Mediated Cancer MRD Surveillance Testing
2026-04-28 20:01 ET
CareDx Announces First Quarter 2026 Financial Results
2026-04-21 20:01 ET
CareDx Announces Presentation of More Than 50 Abstracts Including 16 Oral Presentations at the International Society for Heart and Lung Transplantation’s 46th Annual Meeting
2026-04-20 11:05 ET
CareDx Introduces AlloSeq Nano at EFI 2026, Expanding HLA Typing Portfolio with Long-Read Sequencing
2026-04-15 20:30 ET
CareDx Announces Agreement to Divest Lab Products Business to EuroBio Scientific for $170 Million and Announces First Quarter Preliminary Financial Results
2026-04-14 20:01 ET
CareDx to Report First Quarter 2026 Financial Results on April 28, 2026
2026-03-05 ET
CareDx Announces VANTx™, an AI‑Powered Clinical Data & Analytics Platform Built on CareDx’s Proprietary, Large-Scale, Longitudinal Solid Organ Transplant Datasets
2026-02-27 ET
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-02-24 ET
CareDx Announces Appointment of Keith Kennedy as Chief Operating Officer and Chief Financial Officer
2026-02-24 ET
CareDx Announces Fourth Quarter and Full Year 2025 Financial Results
2026-02-18 13:00 ET
CareDx to Participate in the Raymond James 47th Annual Institutional Investors Conference
2026-02-12 12:05 ET
CareDx Announces Clinical Validation Results for AlloHeme™, the First AI‑Powered NGS Surveillance Solution for AML and MDS Post‑Cell Therapy
2026-02-10 21:01 ET
CareDx to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
2026-02-03 12:05 ET
CareDx to Present AlloHeme™ Pivotal Clinical Validation Data in Hematologic Cancer Relapse Detection at 2026 Tandem Meetings
2026-01-27 21:05 ET
CareDx to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference 
2026-01-12 12:05 ET
CareDx Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results
2025-12-26 21:05 ET
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-11-24 21:05 ET
SHORE Study Demonstrates HeartCare's Prognostic Value for Heart Transplant Recipients, Published in Journal of Heart and Lung Transplantation
2025-11-10 ET
CareDx to Participate in Upcoming Investor Conferences
2025-11-07 ET
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-11-06 ET
CareDx Announces New Precision Kidney Transplant Data and Product Innovations at ASN Kidney Week 2025
2025-11-04 ET
CareDx Announces Third Quarter 2025 Financial Results
2025-10-27 ET
CareDx Announces Appointment of Jeffrey John Teuteberg, MD as Chief Medical Officer
2025-10-23 ET
CareDx Announces Largest Landmark Study of Its Kind on Antibody Mediated Rejection in Heart Transplantation Published in Journal of the American College of Cardiology: Heart Failure
2025-10-22 ET
CareDx Announces Appointment of Suresh Gunasekaran to Board of Directors
2025-10-21 ET
CareDx to Report Third Quarter 2025 Financial Results on November 4, 2025
2025-10-06 ET
CareDx Announces New IVD Products and IVDR Certification for AlloSeq® Tx and QTYPE® at the 2025 American Society of Histocompatibility & Immunogenetics Annual Meeting
2025-09-02 ET
CareDx Issues Comment Letter on Draft LCD Policy
2025-08-21 ET
CareDx to Participate in Wells Fargo Healthcare Conference
2025-08-06 ET
CareDx Announces Appointment of Nathan Smith as Chief Financial Officer
2025-08-06 ET
CareDx Announces Landmark KOAR Study Published in the American Journal of Transplantation
2025-07-31 ET
CareDx Announces Landmark Data in AI-Powered Transplant Diagnostics Showcased in Over 40 Abstracts and 16 Oral Presentations at the 2025 World Transplant Congress
2025-07-23 ET
CareDx to Report Second Quarter 2025 Financial Results
2025-07-18 ET
CareDx Announces Proposed Draft LCD That Affirms Surveillance Testing Coverage for Solid Organ Transplant Rejection
2025-06-03 ET
CareDx Announces Repurchase of 5% of Outstanding Shares
2025-05-13 ET
CareDx to Participate in Upcoming Investor Conferences
2025-04-30 ET
CareDx Reports First Quarter 2025 Results
2025-04-29 ET
CareDx Announces New Data on AlloSure Lung Presented at 2025 International Society for Heart and Lung Transplantation Meeting
2025-04-24 ET
CareDx Announces Presentation of 60 Abstracts Including 19 Oral Presentations at the 2025 International Society for Heart and Lung Transplantation Meeting
2025-04-21 ET
CareDx Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
2025-04-08 ET
CareDx to Report First Quarter 2025 Financial Results
2025-03-11 ET
CareDx Launches Two Expanded Indications for AlloSure Testing Services
2025-02-26 ET
CareDx Announces Fourth Quarter and Full Year 2024 Financial Results
2025-02-25 ET
CareDx Announces District Court Reverses Jury Decision in Patent Infringement Case Overturning Prior $96 Million Verdict
2025-02-20 ET
CareDx Announces Study Showing AlloSeq cfDNA Highly Accurate in Detecting Rejection in Organ Transplant Patients
2025-02-13 ET
CareDx Announces Presentation of Data at 2025 Tandem Meetings Demonstrating Strong Performance of AlloHeme in Early Relapse Detection for Hematologic Malignancies
2025-02-11 ET
CareDx to Report Fourth Quarter and Full Year 2024 Financial Results
2025-01-13 ET
CareDx Announces Preliminary Fourth Quarter and Full Year 2024 Results
2024-12-18 ET
CareDx to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
2024-12-11 ET
CareDx Partners with TC BioPharm to Support ACHIEVE Clinical Trial Using AlloCell for Pharmacokinetic Monitoring of Allogeneic Cell Therapy
2024-12-11 ET
TCBP Partners with CareDx to Support ACHIEVE Clinical Trial Using AlloCell for Pharmacokinetic Monitoring of Allogeneic Cell Therapy
2024-11-12 ET
CareDx to Participate in Upcoming Investor Conferences
2024-11-04 21:05 ET
CareDx Reports Third Quarter 2024 Results and Raises Revenue Guidance
2024-10-23 11:00 ET
CareDx and Dovetail Genomics Announce Strategic Partnership to Drive Next Wave of Innovation in Transplant Matching with Cutting-Edge Hi-C Technology
2024-10-21 11:00 ET
CareDx Showcases Latest Advancements Across its HLA Typing Solutions at Annual American Society for Histocompatibility and Immunogenetics Meeting
2024-10-15 10:00 ET
CareDx Reports Preliminary Financial Results for Third Quarter 2024
2024-10-11 20:30 ET
CareDx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2024-10-09 11:05 ET
CareDx Appoints Jing Huang Chief Data and AI Officer
2024-10-08 20:05 ET
CareDx to Host Investor Day on October 15, 2024
2024-10-08 10:05 ET
CareDx Announces Closure of DOJ Investigation with No Finding of Wrongdoing
2024-09-14 00:35 ET
CareDx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2024-09-14 00:33 ET
CareDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-09-12 11:01 ET
CareDx Appoints Keith Kennedy Chief Operating Officer and Jessica Meng Chief Commercial Officer
2024-08-16 18:10 ET
CareDx Announces Transplant Community Secures Win Reaffirming Longstanding Medicare Coverage for AlloSure and AlloMap Testing
2024-07-31 20:05 ET
CareDx Reports Second Quarter 2024 Results and Increases Revenue Guidance
2024-07-16 11:05 ET
CareDx to Report Second Quarter 2024 Financial Results
2024-06-03 11:05 ET
Landmark Independent Publication in Nature Medicine Validates CareDx AlloView AI-Enabled Risk Prediction Model and Demonstrates AlloSure Kidney Detects Subclinical Rejection in Stable Patients
2024-05-30 11:05 ET
AI Integration and Real-World Utility of CareDx Portfolio Highlighted in New Data at the 2024 American Transplant Congress
2024-05-29 12:05 ET
CareDx Reiterates Position that it Does Not Infringe the ‘544 Patent, Injunction Motion is Irrelevant
2024-05-29 11:05 ET
CareDx to Participate in Upcoming Investor Conferences
2024-05-16 20:05 ET
Landmark Study Shows CareDx’s HeartCare Outperforms dd-cfDNA Alone in Identifying Rejection and Patients Experienced Excellent Outcomes with Fewer Biopsies
2024-05-09 20:05 ET
CareDx Reports First Quarter 2024 Results
2024-05-03 20:10 ET
CareDx Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2024-04-29 20:05 ET
CareDx to Report First Quarter 2024 Financial Results
2024-04-19 20:05 ET
CareDx Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
2024-04-16 20:02 ET
CareDx Appoints John W. Hanna as its New President and Chief Executive Officer
2024-04-09 11:00 ET
CareDx and Collaborators Present Latest Cardiothoracic Advancements at the 2024 International Society for Heart and Lung Transplantation Meeting
2024-03-11 20:10 ET
CareDx Appoints Bryan Riggsbee to Its Board of Directors
2024-02-28 21:05 ET
CareDx Announces Fourth Quarter and Full Year 2023 Financial Results
2024-02-27 21:05 ET
CareDx to Participate in the Raymond James & Associates’ 45th Annual Institutional Investors Conference
2024-02-21 21:05 ET
CareDx to Report Fourth Quarter and Full Year 2023 Financial Results
2024-02-21 12:00 ET
CareDx Showcases Digital Solutions and Pipeline in Cellular Transplant and Therapy Monitoring at the 2024 Tandem Meetings
2024-01-27 02:45 ET
CareDx Issues Statement in Patent Infringement Case
2024-01-11 21:05 ET
CareDx Adds to AlloSure Kidney and HeartCare Utility and Clinical Data at 2024 American Society of Transplant Surgeons Winter Symposium
2024-01-09 12:00 ET
CareDx Reports Preliminary Revenue Results for Fourth Quarter and Full Year 2023
2023-12-19 12:00 ET
CareDx Joins Forces with the National Foundation for Transplants to Improve Post-Transplant Medication Adherence
2023-11-08 21:05 ET
CareDx Reports Third Quarter 2023 Results
2023-11-02 20:05 ET
CareDx to Report Third Quarter 2023 Financial Results
2023-11-01 20:02 ET
CareDx Announces CEO Transition
2023-10-17 11:00 ET
CareDx Presents New Data at the American Society for Histocompatibility and Immunogenetics Annual Meeting
2023-10-03 22:00 ET
CareDx Issues Statement on Supreme Court Decision Regarding Stanford-Licensed Patents
2023-09-19 11:00 ET
CareDx To Present at the 2023 Cantor Global Healthcare Conference
2023-09-14 06:00 ET
CareDx Advances Global Transplant Patient Care at ESOT Congress 2023
2023-08-31 11:00 ET
CareDx To Present at the H.C. Wainwright 25th Annual Global Investment Conference
2023-08-17 11:00 ET
CareDx Hosts Second Annual MEET Digital Health User Conference to Showcase Latest Innovations to Enhance Transplant Patient Care
2023-08-11 11:00 ET
CareDx Comments on Issuance of Proposed LCD for Molecular Testing for Solid Allograft Rejection
2023-08-08 20:05 ET
CareDx Reports Second Quarter 2023 Results
2023-08-07 15:08 ET
CareDx Announces District Court Judge Bars Natera from Falsely Advertising and Overstating the Scientific Performance of its Prospera Transplant Test
2023-08-03 11:00 ET
CareDx to Report Second Quarter 2023 Financial Results
2023-08-02 11:00 ET
CareDx’s HeartCare Multimodality Service Receives Medicare Coverage for Heart Transplant Surveillance
2023-07-25 11:00 ET
CareDx Acquires MediGO, an Organ Transplant Supply Chain and Logistics Company
2023-07-18 03:42 ET
CareDx Applauds District Court Decision to Uphold Jury Verdict that Natera Falsely Advertised its Prospera Transplant Test
2023-07-11 11:00 ET
CareDx’s AlloSure Lung dd-cfDNA Testing Service Receives Medicare Coverage for Lung Transplant Rejection Monitoring
2023-06-01 12:00 ET
CareDx Demonstrates Innovation Leadership at 2023 Transplant Congress
2023-06-01 11:00 ET
CareDx to Participate in Upcoming Investor Conferences
2023-05-16 11:00 ET
CareDx Showcases Digital Health Portfolio at 31st Annual UNOS Transplant Management Forum
2023-05-10 20:05 ET
CareDx Reports First Quarter 2023 Results
2023-05-08 11:01 ET
CareDx to Report First Quarter 2023 Financial Results
2023-04-25 10:01 ET
CareDx Showcases Latest Advances Across AlloSeq Lab Products Portfolio at the 36th European Immunogenetics and Histocompatibility Conference
2023-04-19 11:01 ET
CareDx Showcases Leadership with Over 55 Oral Presentations and Posters at the 43rd Annual Meeting & Scientific Sessions of the International Society for Heart and Lung Transplantation
2023-04-06 11:01 ET
National Kidney Foundation Honors CareDx with Corporate Citizenship Award for its Commitment to the Transplant Community
2023-03-23 11:01 ET
CareDx Presents Latest Advancements at 12th Congress of the International Pediatric Transplant Association
2023-03-07 12:01 ET
The American Society of Transplant Surgeons Position Statement Supports Use of CareDx’s AlloSure Kidney for Organ Transplant Surveillance
2023-03-06 21:32 ET
CareDx Update Regarding Raymond James & Associates’ Conference
2023-03-06 12:01 ET
CareDx To Participate in the Raymond James & Associates’ 44th Annual Institutional Investors Conference
2023-03-03 12:01 ET
CareDx Comments on MolDX Publication of New Billing and Coding Article
2023-03-01 12:01 ET
CareDx Key Supporter of the National Kidney Foundation’s Annual Kidney Patient Summit
2023-02-27 21:01 ET
CareDx Reports Fourth Quarter and Full Year 2022 Results
2023-02-22 12:01 ET
CareDx Showcases Clinical Value of Multimodality and AI Innovation at the American Society of Transplantation Cutting Edge of Transplantation Meeting
2023-02-21 21:01 ET
CareDx to Report Fourth Quarter and Full Year 2022 Financial Results
2023-02-16 12:01 ET
CareDx Showcases Latest Advancements in Cellular Transplant and Therapy Including Specialized Digital Health Solutions at the 2023 Tandem Meetings
2023-01-26 12:01 ET
JACC Publication Guides Use of CareDx’s HeartCare Transplant Rejection Surveillance in Clinical Practice
2023-01-11 12:01 ET
CareDx Fosters Transplant Innovation as Distinguished Founder’s Circle Sponsor for the 23rd Annual American Society of Transplant Surgeons State of the Art Winter Symposium
2023-01-09 12:00 ET
CareDx Reports Preliminary Revenue Results for Fourth Quarter and Full Year 2022
2022-12-21 23:00 ET
New ISHLT Guidelines Support Use of CareDx’s HeartCare Solutions, AlloMap and AlloSure, in Routine Monitoring of Heart Transplant Patients
2022-12-06 13:01 ET
CareDx Announces $50 Million Stock Repurchase Program
2022-12-01 13:15 ET
Independent Prospective Study Defines Reference Range for CareDx’s AlloSure for Long-Term Lung Transplant Surveillance
2022-11-11 12:01 ET
CareDx Committed to Delivering Clinical Innovation to the Transplant Patient and Physician Community
2022-11-04 11:00 ET
CareDx To Participate in Upcoming Investor Conferences
2022-11-03 20:01 ET
CareDx Reports Third Quarter 2022 Results
2022-11-02 11:01 ET
CareDx Demonstrates Power of AlloSure and Digital Health Transplant Solutions at American Society of Nephrology Kidney Week
2022-11-01 11:01 ET
Independent Longitudinal Study Finds CareDx’s AlloSure Detects Early Signs of Rejection in Pediatric Kidney Transplant Patients
2022-10-27 11:01 ET
CareDx Congratulates C-Path's Transplant Therapeutics Consortium and Paris Transplant Group for Receiving EMA Draft Qualification for iBox Scoring System
2022-10-26 11:30 ET
CareDx to Report Third Quarter 2022 Financial Results
2022-10-26 11:01 ET
CareDx Joins Forces with National Kidney Foundation and Honor the Gift Coalition to Host Immuno Bill Webinar for Kidney Transplant Patients
2022-10-25 11:01 ET
CareDx Presents Latest Data on AlloSeq NGS Solutions and Transplant Innovation at the American Society for Histocompatibility and Immunogenetics Annual Meeting
2022-09-29 11:01 ET
CareDx to Host Symposium Covering Innovation in Multimodal Surveillance Including AiCAV for Post-Cardiac Transplant Care
2022-09-27 11:01 ET
Transplant Patients Experience Less Pain and Fewer Adverse Events with CareDx Non-Invasive Testing Solutions
2022-09-26 12:43 ET
CareDx Congratulates Board Member Dr. Grace Colón for Being Named Healthcare Innovator on Top 50 Most Powerful Latinas List
2022-09-19 11:01 ET
CareDx Showcases Transplant Digital Leadership in Patient Care at 2022 MEET Conference
2022-09-14 11:01 ET
CareDx Celebrates 1 Million Organ Transplants and 100,000 Patient Milestone
2022-09-12 11:01 ET
CareDx Demonstrates Global Leadership at 29th International Congress of The Transplantation Society
2022-08-11 11:01 ET
CareDx and MOTTEP Co-Host Health Equity Summit
2022-08-04 20:01 ET
CareDx Reports Second Quarter 2022 Results
2022-08-04 11:01 ET
CareDx Unveils New Patient-Centered Medication Management Features on AlloCare Mobile Health App
2022-08-02 11:01 ET
CareDx Launches Personalized AlloHome Patient Monitoring Solution to Augment Pre- and Post-Transplant Care
2022-07-28 12:00 ET
CareDx to Report Second Quarter 2022 Financial Results
2022-07-28 11:01 ET
CareDx Demonstrates Industry-Leading Commitment to Advancing Transplant Innovation as Distinguished Founder’s Circle Sponsor for the 2022 American Society of Transplant Surgeons Symposium
2022-06-28 11:01 ET
CareDx Lead Sponsor for 2022 Donate Life Transplant Games
2022-06-21 11:01 ET
CareDx The Transplant Company Releases Inaugural Environmental, Social and Governance Report
2022-06-09 22:20 ET
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In CareDx To Contact Him Directly To Discuss Their Options
2022-06-02 20:01 ET
CareDx To Participate in Upcoming Jefferies Healthcare Conference
2022-06-02 11:01 ET
CareDx Leads Transplant Innovation with AiKidney, an AI Clinical Decision Support Tool for Predicting Allograft Rejection Risk
2022-06-01 11:01 ET
CareDx Innovation Showcased in Record-Breaking Number of Scientific Abstracts with Over 50 Presented at 2022 Transplant Congress
2022-05-24 10:00 ET
CareDx Receives CE Mark for AlloSeq HCT for Use in Hematopoietic Cell Transplantation
2022-05-24 10:00 ET
CareDx Receives CE Mark for AlloSeq HCT for Use in Hematopoietic Cell Transplantation
2022-05-18 11:00 ET
CareDx Sponsored ISHLT Innovation Challenge Award Tackles Chronic Lung Allograft Dysfunction
2022-05-17 11:00 ET
In CareDx-Initiated IP Litigation Against Natera, Natera Now Drops 1 of 2 Patents Originally Asserted Against CareDx
2022-05-11 11:00 ET
CareDx Showcases Latest Innovation in Transplantation at European EFI 2022 Conference
2022-05-11 11:00 ET
CareDx Showcases Latest Innovation in Transplantation at European EFI 2022 Conference
2022-05-05 20:01 ET
CareDx Reports First Quarter 2022 Results
2022-05-05 11:00 ET
CareDx Validates Clinical Performance of AlloMap Kidney to Comprehensively Assess Transplant Rejection
2022-04-28 14:45 ET
CareDx Congratulates Board Member Dr. Hannah Valantine on ISHLT Lifetime Achievement Award
2022-04-28 11:00 ET
CareDx Extends Artificial Intelligence Leadership to Heart Transplantation
2022-04-27 20:01 ET
CareDx to Report First Quarter 2022 Financial Results
2022-04-27 13:15 ET
International Society for Heart and Lung Transplantation Foundation Selects Reg Seeto as Corporate Chair
2022-04-22 11:00 ET
CareDx Demonstrates Potential of AlloHeme and AlloCell for Allogeneic Cell Transplant and Therapy Monitoring at Transplantation & Cellular Therapy Meetings
2022-04-21 11:10 ET
CareDx Supports UC Davis Health Pluralist Program Aimed at Reducing Health Disparities in Organ Transplantation
2022-04-20 11:00 ET
CareDx Showcases Leadership with Over 25 Oral Presentations and Posters at the International Society for Heart and Lung Transplantation Meeting
2022-04-14 11:41 ET
CareDx Reports Over 200,000 Heart Transplant Patient Results Served
2022-04-11 11:00 ET
CareDx, the Leading Sponsor of UNOS Transplant Management Forum, Demonstrates the Value of Digital Solutions to Improve Pre-Transplant Patient Referral and Waitlisting Workflow
2022-04-06 11:00 ET
CareDx to Host Symposium at CEoT Featuring the Latest Multimodality Innovations in Kidney and Lung Transplant Surveillance
2022-03-30 11:00 ET
CareDx Partners with the European Society for Organ Transplantation to Provide Clinical Evidence Supporting the Use of AlloSeq cfDNA with European Transplant Healthcare Professionals
2022-03-30 11:00 ET
CareDx Partners with the European Society for Organ Transplantation to Provide Clinical Evidence Supporting the Use of AlloSeq cfDNA with European Transplant Healthcare Professionals
2022-03-29 11:00 ET
CareDx Partners with HeartBrothers Foundation to Help Patients Living with Heart Failure and Heart Transplant
2022-03-24 11:00 ET
CareDx’s AlloCare App Now Integrated with TxAccess to Help Pre-Transplant Patients Navigate the Waitlist Process
2022-03-23 11:00 ET
CareDx Announces XenoSure and XenoMap
2022-03-16 11:00 ET
CareDx Brings Together Leading Transplant Experts to Share Latest Advancements in the Field of Xenotransplantation
2022-03-03 12:00 ET
CareDx Announces Cibiltech Initiates CIBIL Study Using iBox Artificial Intelligence to Monitor Kidney Transplant Patients
2022-03-03 12:00 ET
CareDx Announces Cibiltech Initiates CIBIL Study Using iBox Artificial Intelligence to Monitor Kidney Transplant Patients
2022-03-02 12:00 ET
CareDx Partners with the National Kidney Foundation to Advocate for Kidney Transplant Patients
2022-02-24 21:01 ET
CareDx Reports Fourth Quarter and Full Year 2021 Results
2022-02-22 12:00 ET
CareDx Leads the Way in Xenotransplant Organ Surveillance in Monitoring World’s First Successful Living Xenotransplantation
2022-02-17 21:01 ET
CareDx to Report Fourth Quarter and Full Year 2021 Financial Results
2022-02-14 12:00 ET
On National Donor Day, CareDx Applauds Patient Advocacy Efforts Aimed at Increasing Donations for the Thousands of Patients Waiting for a Transplant
2022-02-08 12:00 ET
CareDx Taps into Its Patient Network to Deliver Insights on Transplant Needs
2022-02-07 12:00 ET
CareDx Joins Forces with MOTTEP, The National Minority Organ Tissue Transplant Education Program, to Host “Heart Health” Webinar for Transplant Patients
2022-02-03 12:00 ET
CareDx To Participate In Upcoming Conferences
2022-01-20 12:00 ET
CareDx Joins Forces with MOTTEP to Increase Organ Donations for Minority Transplant Patients and Support High-Risk, Underserved Communities
2022-01-12 12:00 ET
Landmark ADMIRAL Study Publication with CareDx’s AlloSure Kidney is the First Long-Term Multicenter Prospective Clinical Validation for Routine Organ Transplant Surveillance
2022-01-11 12:00 ET
CareDx Partners with Multiple Biotechnology Companies to Use AlloCell in CAR T-Cell Therapy Clinical Studies
2022-01-10 12:00 ET
CareDx Reports Preliminary Revenue Results for Fourth Quarter and Full Year 2021
2022-01-07 12:00 ET
NIH Study Shows Using CareDx’s AlloSure Lung for Transplant Surveillance is More Effective than Diagnostic Bronchoscopy at Identifying Rejection
2022-01-06 12:00 ET
CareDx Successfully Completes CLIA Validation of AlloMap Kidney in Preparation for Commercial Launch
2022-01-05 12:00 ET
CareDx Expands Its Medication Adherence Services with the Acquisition of The Transplant Pharmacy
2022-01-04 12:00 ET
CareDx Partners with ISHLT in a Transplant Innovation Research Grant to Improve Outcomes for Heart and Lung Transplant Patients
2021-12-16 12:00 ET
CareDx Enrolls First Patient in LungCare Registry Study to Measure Impact of Multimodality Assessment on Lung Transplant Patient Outcomes
2021-12-13 12:00 ET
CareDx Partners with the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) Organization in Launching Prospective, Multi-Center Pediatric Kidney Transplant Study
2021-12-02 12:00 ET
CareDx The Transplant Company Surpasses 80,000 Patient Milestone
2021-11-19 12:00 ET
CareDx Named One of the Fastest-Growing Companies in North America on the Deloitte Technology Fast 500™ for the Third Consecutive Year
2021-11-18 12:00 ET
CareDx Enrolls First Patients in the Largest Digital Study in Transplant Using AlloCare to Assess Patient Outcomes
2021-11-15 21:05 ET
CareDx To Participate in Upcoming Conferences
2021-11-10 12:00 ET
CareDx Acquires MedActionPlan to Directly Support Patients with Better Adherence
2021-11-04 11:00 ET
University of Alabama Integrates CareDx’s TxAccess for Connection to Over 500 Community Practices
2021-11-03 11:00 ET
CareDx Focuses on Innovation in Transplant at ASN Kidney Week
2021-11-01 20:01 ET
CareDx Completes Orderly Management Transition
2021-10-28 20:01 ET
CareDx Reports Third Quarter 2021 Results; Increases Full Year Revenue Guidance
2021-10-21 11:00 ET
CareDx’s AlloSure Demonstrates Better Accuracy Than Current Standards of Care in Independent Kidney Transplant Study
2021-10-19 11:00 ET
CareDx and Eledon Pharmaceuticals Announce Collaborative Research Agreement
2021-10-14 20:01 ET
CareDx to Report Third Quarter 2021 Financial Results
2021-10-12 14:18 ET
AlloSure, the First dd-cfDNA in Heart and Kidney Transplantation, Launches for Lung Transplant Patients
2021-09-30 20:01 ET
CareDx Extends Leadership in Multimodality Transplant Care with KidneyCare Validation Publication
2021-09-28 23:18 ET
CareDx Continues to Fight for Innovation in Transplantation
2021-09-27 11:00 ET
CareDx Presents Latest Data on AlloSeq Portfolio at ASHI 2021
2021-09-15 12:00 ET
CareDx Names Longtime Patient Advocate Art Torres to Board of Directors
2021-09-02 11:00 ET
CareDx to Participate in Upcoming Conferences
2021-08-26 11:00 ET
CareDx Showcases Leadership in Global Transplantation at ESOT 2021
2021-07-29 20:01 ET
CareDx Reports 77% Revenue Growth for Second Quarter of 2021 and Increases Full Year Revenue Guidance
2021-07-26 11:00 ET
CareDx Launches ACROBAT Study to Potentially Change Care Paradigm for Stem Cell Transplant Patients
2021-07-19 11:40 ET
Medexus Appoints New Chief Financial Officer
2021-07-15 11:00 ET
CareDx to Report Second Quarter 2021 Financial Results
2021-07-01 20:01 ET
CareDx Transplant Patient App, AlloCare, Expands Access to the Majority of Transplant Patients
2021-06-30 11:00 ET
CareDx Appoints Dr. Hannah Valantine to its Board of Directors
2021-06-17 11:00 ET
CareDx CEO Reg Seeto to Present at AAKP 4th Annual Policy Summit
2021-06-16 11:00 ET
CareDx to Participate in Raymond James 2021 Human Health Innovation Conference
2021-06-15 11:00 ET
CareDx Hosts Fireside Chat with Pro Golfer and Heart Transplant Recipient Erik Compton
2021-06-09 11:00 ET
CareDx congratulates Hannah Valantine for her State of the Art Lecture at ATC on Transplant Equity
2021-06-08 11:00 ET
CareDx To Acquire Transplant Hero Medication Management Application
2021-06-07 11:00 ET
CareDx Presents Landmark KOAR-1000 Data, Demonstrating Higher 1-Year Graft Survival and Reduction in Biopsies through ARTS Surveillance
2021-06-04 11:00 ET
CareDx Presents Groundbreaking AlloSure® Data at the 2021 American Transplant Congress
2021-06-03 20:05 ET
CareDx Advances Artificial Intelligence in Transplantation
2021-06-03 11:00 ET
CareDx to Participate in 42nd Annual Goldman Sachs Global Healthcare Conference
2021-06-01 12:09 ET
CareDx Starts Enrollment in MAPLE, a Multi-modal, Multi-center, Prospective Study of LiverCare
2021-05-28 22:00 ET
CareDx Announces Strategic Minority Investment in Miromatrix
2021-05-27 11:00 ET
CareDx to Participate in Jefferies Healthcare Conference
2021-05-13 11:00 ET
CareDx to Participate in AAKP and George Washington University Global Summit on Kidney Disease Innovations
2021-05-05 20:01 ET
CareDx Reports First Quarter 2021 Results
2021-04-23 11:00 ET
CareDx to Present New Heart Transplant Data at the International Society for Heart and Lung Transplantation Annual Meeting
2021-04-22 15:37 ET
Palmetto MolDx Issues Foundational Coverage for Molecular Testing in Solid Organ Allograft Rejection
2021-04-22 11:00 ET
CareDx to Debut Multicenter Data on AlloSure® Lung, an Analytically and Clinically Validated Biomarker of Graft Injury for Lung Transplant Patients
2021-04-21 20:00 ET
CareDx to Report First Quarter 2021 Financial Results
2021-04-20 11:00 ET
CareDx Showcases Transplantation Innovation and Leadership in Europe at EFI 2021
2021-04-16 11:00 ET
CareDx to Present at UNOS Transplant Management Forum
2021-04-08 11:00 ET
CareDx Announces New HLA Typing Service Offering for Research Purposes
2021-04-05 11:00 ET
CareDx to Participate in National Kidney Foundation 2021 Spring Clinical Meetings
2021-03-31 11:00 ET
CareDx Enhances Leadership Team with Key Appointments
2021-03-23 11:00 ET
CareDx Supports Vir Biotechnology’s Clinical Trial Recruitment Efforts for COMET-ICE
2021-03-17 11:00 ET
CareDx Strengthens Bioinformatics Capabilities with Acquisition of BFS Molecular
2021-03-11 21:05 ET
CareDx Names Ankur Dhingra as New Chief Financial Officer
2021-02-25 12:00 ET
CareDx Expands into the Pre-Transplant Kidney Space through TX Connect
2021-02-24 21:01 ET
CareDx Reports Fourth Quarter and Full Year 2020 Results
2021-02-23 12:00 ET
Spotlight on the CareDx’s Symposium at the Upcoming Cutting Edge of Transplantation (CEoT) Meeting
2021-02-12 12:00 ET
CareDx to Report Fourth Quarter and Full Year 2020 Financial Results
2021-02-11 12:00 ET
CareDx Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
2021-02-10 12:00 ET
CareDx to to Participate in Upcoming BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
2021-02-05 12:00 ET
CareDx Showcases Cellular Transplantation and Therapy Portfolio at TCT
2021-01-25 21:27 ET
CareDx Announces Closing of Public Offering of Common Stock
2021-01-21 03:56 ET
CareDx Announces Pricing of Public Offering of Common Stock
2021-01-19 21:14 ET
CareDx Announces Proposed Public Offering of Common Stock
2021-01-11 12:00 ET
CareDx Reports Preliminary Fourth Quarter and Full Year 2020 Results
2021-01-08 12:01 ET
CareDx Agrees to Acquire TransChart and Expands EMR Connectivity to Over 90 Centers
2021-01-08 12:00 ET
CareDx Transplant Leadership Showcased at ASTS 2021
2021-01-07 12:00 ET
CareDx Announces AlloID and Exclusive Partnership with IDbyDNA
2021-01-04 12:00 ET
CareDx’s AlloSeq HCT Wins Tender for French Stem Cell Transplant Patient Surveillance
2020-12-22 14:59 ET
CareDx Celebrates the Long-Awaited Passage of the Immuno Bill
2020-12-01 12:00 ET
CareDx Announces First AlloSure Pediatrics Publication
2020-11-25 12:00 ET
CareDx to Participate in Upcoming Piper Sandler 32nd Annual Virtual Healthcare Conference
2020-11-17 10:00 ET
CareDx Receives Medicare Reimbursement Pricing for AlloSure Heart
2020-11-10 12:00 ET
CareDx to Participate at Upcoming Conferences
2020-11-06 12:05 ET
New Publication Shows CareDx’s AlloSure May Be Effective for Monitoring BK Virus in Transplant Patients
2020-11-06 12:00 ET
CareDx Joins National Kidney Foundation in Virtual Walk for Kidney Patients
2020-10-29 20:06 ET
Peter Maag Appointed Executive Chairman of the Board of Directors of CareDx; Reginald Seeto Appointed President and CEO
2020-10-29 20:05 ET
CareDx Reports Third Quarter 2020 Results
2020-10-21 11:00 ET
CareDx Showcases Leading Transplant Data at ASN 2020
2020-10-19 11:05 ET
Medicare Proposes to Maintain Current Reimbursement Process for AlloMap
2020-10-19 11:00 ET
CareDx Leads in Innovation with AlloSeq Portfolio at ASHI 2020
2020-10-15 20:05 ET
CareDx to Report Third Quarter 2020 Financial Results
2020-10-07 20:05 ET
CareDx Reports Preliminary Third Quarter 2020 Revenue
2020-10-02 11:00 ET
CareDx Announces Publication of Pivotal AlloSure Lung Data
2020-10-01 13:50 ET
CareDx Receives Final Medicare Coverage Decision for AlloSure Heart
2020-09-24 11:00 ET
CareDx Launches AlloCare at Virtual Transplant Festival
2020-09-11 11:00 ET
CareDx Shares Latest Clinical Data at the TTS 2020 Virtual Conference
2020-09-10 11:00 ET
CareDx Strengthens Leadership Team to Accelerate Growth
2020-09-02 11:00 ET
CareDx to Participate at Upcoming Conferences
2020-08-04 20:05 ET
CareDx Reports Second Quarter 2020 Results
2020-07-30 11:00 ET
CareDx to Participate at the Canaccord Genuity 40th Annual Growth Conference
2020-07-16 20:05 ET
CareDx to Report Second Quarter 2020 Financial Results
2020-07-15 11:00 ET
CareDx Chairman and CEO Peter Maag to Present at Global Kidney Innovations Summit
2020-06-22 11:00 ET
New Kidney360 Publication Highlights CareDx’s AlloSure is Differentiated as the dd-cfDNA Test of Choice
2020-06-18 20:05 ET
CareDx Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
2020-06-18 11:00 ET
FDA Accepts Letter of Intent for iBox Scoring System as a Surrogate Endpoint in Pharmaceutical Clinical Trials
2020-06-15 20:05 ET
CareDx Announces Closing of Public Offering of Common Stock
2020-06-11 00:11 ET
CareDx Announces Pricing of Public Offering of Common Stock
2020-06-09 21:13 ET
CareDx Announces Proposed Public Offering of Common Stock
2020-06-08 21:00 ET
CareDx Announces 2020 Annual Meeting of Stockholders to be Held as a Virtual Meeting
2020-06-04 11:00 ET
CareDx to Participate at the Goldman Sachs Global Healthcare Conference
2020-05-28 11:00 ET
CareDx to Present at the Jefferies Virtual Healthcare Conference
2020-05-27 11:00 ET
CareDx Presents the Latest AlloSure Data in Virtual Meetings
2020-05-15 11:00 ET
CareDx's AlloSeq Tx 17 Awarded CE Mark Approval
2020-05-07 11:00 ET
CareDx Brings the Transplant Patient Community Together
2020-05-05 11:00 ET
CareDx Collaborates with Weill Cornell Medicine to Lead the Development and Commercialization of UroMap
2020-04-30 20:05 ET
CareDx Reports First Quarter 2020 Results
2020-04-27 11:00 ET
CareDx Engages European Lab Community in Virtual Meetings
2020-04-23 11:00 ET
CareDx and Johns Hopkins Partner on AlloSure Lung Surveillance
2020-04-22 11:00 ET
CareDx Presents New Heart and Lung Transplant Data in Virtual Meetings
2020-04-21 11:00 ET
CareDx to Report First Quarter 2020 Financial Results
2020-04-14 11:00 ET
CareDx Introduces AlloCell: Cell Therapy Surveillance
2020-04-09 11:00 ET
CareDx Mobilizes 10,000 Phlebotomists for Home Blood Draws of Transplant Patients with RemoTraC
2020-04-08 20:01 ET
CareDx Reports Preliminary First Quarter 2020 Revenue and Provides Business Update in Response to COVID-19 Pandemic
2020-04-06 11:00 ET
CareDx Supports Launch of International COVID-19 Transplant Registry (C19TxR)
2020-03-20 11:00 ET
REPEAT - New AJT Publication: AlloSure Monitors First Patient Retransplanted After Anti-PD-L1 Cancer Therapy
2020-03-20 05:05 ET
New AJT Publication: AlloSure Monitors First Patient Retransplanted After Anti-PD-L1 Cancer Therapy
2020-03-17 11:00 ET
CareDx Launches RemoTraC: Home-Based Monitoring of Transplant Patients
2020-03-12 11:00 ET
CareDx Joins National Kidney Foundation on World Kidney Day to Support Kidney Transplant Community
2020-03-05 12:00 ET
CareDx Brings Personalized Care to Transplant with the Launch of KIRA Immuno-optimization Study at CEOT
2020-02-28 12:00 ET
CareDx to Participate in Upcoming Investor Conferences
2020-02-27 21:05 ET
CareDx Reports Fourth Quarter and Full Year 2019 Results
2020-02-26 12:00 ET
New AJT Publication: AlloSure is the Only cfDNA Test Proven to Differentiate Ambiguous Rejections
2020-02-13 12:00 ET
CareDx to Report Fourth Quarter and Full Year 2019 Financial Results on February 27, 2020
2020-02-11 12:00 ET
CareDx’s Patent Rights Upheld By Delaware Court
2020-02-04 12:00 ET
CareDx Launches AiTraC Conference
2020-01-13 12:00 ET
CareDx Reports Preliminary Fourth Quarter and Full Year 2019 Results
2020-01-10 12:00 ET
CareDx’s AlloSeq cfDNA Awarded CE Mark Approval
2020-01-09 12:00 ET
CareDx Leadership at ASTS Meeting
2020-01-08 12:00 ET
CareDx's False Advertising Complaint Upheld By Court
2019-12-24 12:00 ET
CareDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2019-12-23 19:38 ET
CareDx Supports Bipartisan Legislation to Protect Kidney Transplant Patients
2019-11-19 12:00 ET
CareDx to Participate in Upcoming Investor Conferences
2019-11-06 12:00 ET
CareDx at ASN Kidney Week
2019-11-04 12:00 ET
CareDx Advances Patient Care with AlloSure 3.0
2019-10-31 20:05 ET
CareDx Reports Third Quarter 2019 Results
2019-10-17 12:00 ET
CareDx to Announce Third Quarter 2019 Financial Results on October 31st, 2019
2019-10-08 12:00 ET
CareDx Participates in Transplant Roundtable with Senator Durbin
2019-09-26 13:25 ET
CareDx Files Patent Infringement Lawsuit Against Eurofins Viracor
2019-09-24 12:00 ET
CareDx Adds HistoMap To Testing Portfolio
2019-09-23 12:00 ET
CareDx’s KidneyCare iBox Technology Clinically Validated in BMJ Publication
2019-09-20 12:00 ET
CareDx Launches AlloSeq® Tx 17 at ASHI/BANFF Meeting
2019-09-18 12:00 ET
First Patient Enrolled in Landmark CareDx OKRA Registry
2019-09-17 12:00 ET
CareDx to Participate in the Cantor Fitzgerald Global Healthcare Conference
2019-09-12 12:00 ET
CareDx launches AlloSeq® cfDNA at ESOT 2019
2019-09-11 20:01 ET
CareDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2019-07-17 19:18 ET
CDNA INVESTIGATION ALERT: Bernstein Liebhard LLP Announces Investigation of CareDx Inc.-- CDNA
2019-07-17 00:03 ET
CDNA INVESTIGATION ALERT: Hagens Berman Alerts CareDx (CDNA) Investors to Investigation of Possible Disclosure Violations
2019-07-16 14:00 ET
Sahm Adrangi's Kerrisdale Capital Issues Negative Report on CareDx, Inc. and Announces Conference Call Schedule
2019-03-11 08:00 ET
AlloSure Heart Clinical Validation Published in Leading Transplant Journal
2019-03-06 21:01 ET
CareDx Reports Fourth Quarter and FY 2018 Results
2019-03-05 13:00 ET
CareDx Welcomes Initiatives from US Government to Support Transplant Care

SEC forms

Show financial reports only

SEC form 10
2026-04-28 20:13 ET
CareDx published news for 2026 q1
SEC form 8
2026-02-24 16:03 ET
CareDx published news for 2025 q4
SEC form 8
2026-02-24 16:03 ET
CareDx reported for 2025 q4
SEC form 10
2025-11-04 16:13 ET
CareDx reported for 2025 q3
SEC form 8
2025-11-04 16:09 ET
CareDx published news for 2025 q3
SEC form 8
2025-11-04 16:09 ET
CareDx reported for 2025 q3
SEC form 10
2025-08-06 20:11 ET
CareDx reported for 2025 q2
SEC form 8
2025-08-06 20:08 ET
CareDx published news for 2025 q2
SEC form 8
2025-08-06 20:08 ET
CareDx reported for 2025 q2
SEC form 8
2025-06-03 20:30 ET
CareDx published news for 2025 q1
SEC form 8
2025-06-03 20:30 ET
CareDx published news for 2025 q1
SEC form 10
2025-04-30 20:18 ET
CareDx published news for 2025 q1
SEC form 10
2025-04-30 00:00 ET
CareDx published news for 2025 q1
SEC form 8
2025-04-30 00:00 ET
CareDx published news for 2025 q1
SEC form 8
2025-04-30 00:00 ET
CareDx reported for 2025 q1
SEC form 10
2025-02-28 00:00 ET
CareDx published news for 2024 q4
SEC form 10
2025-02-27 22:49 ET
CareDx published news for 2024 q4
SEC form 8
2025-02-26 00:00 ET
CareDx published news for 2024 q4
SEC form 8
2025-02-26 00:00 ET
CareDx reported for 2024 q4
SEC form 8
2025-01-13 00:00 ET
CareDx published news for 2024 q4
SEC form 8
2025-01-13 00:00 ET
CareDx published news for 2024 q4
SEC form 8
2025-01-13 00:00 ET
CareDx published news for 2024 q4
SEC form 10
2024-11-04 16:18 ET
CareDx published news for 2024 q3
SEC form 8
2024-11-04 16:10 ET
CareDx published news for 2024 q3
SEC form 8
2024-11-04 16:10 ET
CareDx published news for 2024 q3
SEC form 8
2024-10-15 00:00 ET
CareDx published news for 2024 q3
SEC form 8
2024-10-15 00:00 ET
CareDx published news for 2024 q3
SEC form 8
2024-10-15 00:00 ET
CareDx published news for 2024 q3
SEC form 10
2024-07-31 16:16 ET
CareDx reported for 2024 q2
SEC form 8
2024-07-31 16:10 ET
CareDx published news for 2024 q2
SEC form 8
2024-07-31 16:10 ET
CareDx published news for 2024 q2
SEC form 8
2024-07-31 16:10 ET
CareDx published news for 2024 q2
SEC form 10
2024-07-31 00:00 ET
CareDx published news for 2024 q2
SEC form 10
2024-05-09 00:00 ET
CareDx published news for 2024 q1
SEC form 8
2024-05-09 00:00 ET
CareDx published news for 2024 q1
SEC form 8
2024-05-09 00:00 ET
CareDx reported for 2024 q1
SEC form 8
2024-05-09 00:00 ET
CareDx published news for 2024 q1
SEC form 10
2024-02-28 16:27 ET
CareDx published news for 2023 q4
SEC form 8
2024-02-28 16:16 ET
CareDx published news for 2023 q4
SEC form 8
2024-02-28 16:16 ET
CareDx reported for 2023 q4
SEC form 10
2024-02-28 00:00 ET
CareDx published news for 2023 q4
SEC form 8
2024-01-09 00:00 ET
CareDx published news for 2023 q4
SEC form 8
2024-01-09 00:00 ET
CareDx published news for 2023 q4
SEC form 8
2024-01-09 00:00 ET
CareDx published news for 2023 q4
SEC form 10
2023-11-08 16:16 ET
CareDx reported for 2023 q3
SEC form 8
2023-11-08 16:11 ET
CareDx published news for 2023 q3
SEC form 10
2023-11-08 00:00 ET
CareDx published news for 2023 q3
SEC form 10
2023-08-08 16:18 ET
CareDx reported for 2023 q2
SEC form 6
2023-08-08 16:11 ET
CareDx published news for 2023 q2
SEC form 10
2023-08-08 00:00 ET
CareDx published news for 2023 q2
SEC form 8
2023-08-08 00:00 ET
CareDx published news for 2023 q2
SEC form 6
2023-06-20 14:52 ET
CareDx published news for 2023 q1
SEC form 10
2023-05-10 00:00 ET
CareDx published news for 2023 q1
SEC form 8
2023-05-10 00:00 ET
CareDx reported for 2023 q1
SEC form 6
2023-04-03 07:00 ET
CareDx published news for 2023 q1
SEC form 6
2023-03-28 16:05 ET
CareDx published news for 2022 q4
SEC form 6
2023-03-10 17:51 ET
CareDx published news for 2022 q4
SEC form 10
2023-02-27 16:28 ET
CareDx published news for 2022 q4
SEC form 6
2023-02-27 16:11 ET
CareDx published news for 2022 q4
SEC form 10
2023-02-27 00:00 ET
CareDx reported for 2022 q4
SEC form 8
2023-02-27 00:00 ET
CareDx reported for 2022 q4
SEC form 6
2023-01-09 07:03 ET
CareDx published news for 2022 q4
SEC form 8
2023-01-09 00:00 ET
CareDx published news for 2022 q4
SEC form 6
2022-12-06 08:01 ET
CareDx published news for 2022 q3
SEC form 6
2022-11-23 16:02 ET
CareDx published news for 2022 q3
SEC form 6
2022-11-03 16:26 ET
CareDx published news for 2022 q3
SEC form 10
2022-11-03 16:23 ET
CareDx published news for 2022 q3
SEC form 10
2022-11-03 00:00 ET
CareDx reported for 2022 q3
SEC form 8
2022-11-03 00:00 ET
CareDx reported for 2022 q3
SEC form 6
2022-09-16 20:38 ET
CareDx published news for 2022 q2
SEC form 6
2022-09-07 16:06 ET
CareDx published news for 2022 q2
SEC form 6
2022-09-01 16:06 ET
CareDx published news for 2022 q2
SEC form 10
2022-08-04 17:20 ET
CareDx published news for 2022 q2
SEC form 6
2022-08-04 16:06 ET
CareDx published news for 2022 q2
SEC form 10
2022-08-04 00:00 ET
CareDx reported for 2022 q2
SEC form 8
2022-08-04 00:00 ET
CareDx reported for 2022 q2
SEC form 6
2022-06-21 17:21 ET
CareDx published news for 2022 q1
SEC form 6
2022-06-21 17:10 ET
CareDx published news for 2022 q1
SEC form 6
2022-06-21 17:07 ET
CareDx published news for 2022 q1
SEC form 6
2022-06-17 13:54 ET
CareDx published news for 2022 q1
SEC form 6
2022-05-23 07:30 ET
CareDx published news for 2022 q1
SEC form 10
2022-05-05 17:13 ET
CareDx published news for 2022 q1
SEC form 6
2022-05-05 16:07 ET
CareDx published news for 2022 q1
SEC form 10
2022-05-05 00:00 ET
CareDx reported for 2022 q1
SEC form 8
2022-05-05 00:00 ET
CareDx reported for 2022 q1
SEC form 6
2022-05-02 13:15 ET
CareDx published news for 2022 q1
SEC form 6
2022-04-14 18:29 ET
CareDx published news for 2022 q1
SEC form 6
2022-03-11 17:15 ET
CareDx published news for 2021 q4
SEC form 10
2022-02-24 17:07 ET
CareDx published news for 2021 q4
SEC form 6
2022-02-24 16:07 ET
CareDx published news for 2021 q4
SEC form 10
2022-02-24 00:00 ET
CareDx published news for 2021 q4
SEC form 8
2022-02-24 00:00 ET
CareDx published news for 2021 q4
SEC form 6
2022-02-03 20:24 ET
CareDx published news for 2021 q4
SEC form 6
2022-01-10 08:38 ET
CareDx published news for 2021 q4
SEC form 8
2022-01-10 00:00 ET
CareDx published news for 2021 q4
SEC form 6
2022-01-06 18:10 ET
CareDx published news for 2021 q4
SEC form 6
2022-01-06 18:08 ET
CareDx published news for 2021 q4
SEC form 6
2022-01-05 08:27 ET
CareDx published news for 2021 q4
SEC form 6
2021-11-10 16:47 ET
CareDx published news for 2021 q3
SEC form 6
2021-11-10 09:06 ET
CareDx published news for 2021 q3
SEC form 6
2021-11-09 18:01 ET
CareDx published news for 2021 q3
SEC form 6
2021-11-01 17:29 ET
CareDx published news for 2021 q3
SEC form 10
2021-10-28 17:21 ET
CareDx published news for 2021 q3
SEC form 6
2021-10-28 16:06 ET
CareDx published news for 2021 q3
SEC form 10
2021-10-28 00:00 ET
CareDx published news for 2021 q3
SEC form 8
2021-10-28 00:00 ET
CareDx published news for 2021 q3
SEC form 6
2021-09-16 17:56 ET
CareDx published news for 2021 q2
SEC form 6
2021-09-15 17:00 ET
CareDx published news for 2021 q2
SEC form 10
2021-07-29 17:10 ET
CareDx published news for 2021 q2
SEC form 6
2021-07-29 16:10 ET
CareDx published news for 2021 q2
SEC form 10
2021-07-29 00:00 ET
CareDx published news for 2021 q2
SEC form 8
2021-07-29 00:00 ET
CareDx published news for 2021 q2
SEC form 6
2021-07-20 18:57 ET
CareDx published news for 2021 q2
SEC form 6
2021-07-20 16:54 ET
CareDx published news for 2021 q2
SEC form 6
2021-07-02 19:27 ET
CareDx published news for 2021 q2
SEC form 6
2021-07-01 16:20 ET
CareDx published news for 2021 q2
SEC form 6
2021-06-17 18:55 ET
CareDx published news for 2021 q1
SEC form 6
2021-06-03 16:05 ET
CareDx published news for 2021 q1
SEC form 10
2021-05-05 17:04 ET
CareDx published news for 2021 q1
SEC form 6
2021-05-05 16:02 ET
CareDx published news for 2021 q1
SEC form 10
2021-05-05 00:00 ET
CareDx published news for 2021 q1
SEC form 8
2021-05-05 00:00 ET
CareDx published news for 2021 q1
SEC form 6
2021-04-30 11:00 ET
CareDx published news for 2021 q1
SEC form 6
2021-04-28 15:07 ET
CareDx published news for 2021 q1
SEC form 6
2021-04-20 15:49 ET
CareDx published news for 2021 q1
SEC form 6
2021-03-25 17:43 ET
CareDx published news for 2020 q4
SEC form 6
2021-03-11 16:07 ET
CareDx published news for 2020 q4
SEC form 10
2021-02-24 17:03 ET
CareDx published news for 2020 q4
SEC form 6
2021-02-24 16:03 ET
CareDx published news for 2020 q4
SEC form 6
2021-01-21 16:56 ET
CareDx published news for 2020 q4
SEC form 6
2021-01-11 07:03 ET
CareDx published news for 2020 q4
SEC form 6
2021-01-05 20:42 ET
CareDx published news for 2020 q4
SEC form 6
2020-12-10 16:02 ET
CareDx published news for 2020 q3
SEC form 10
2020-10-29 17:11 ET
CareDx published news for 2020 q3
SEC form 6
2020-10-29 16:13 ET
CareDx published news for 2020 q3
SEC form 6
2020-10-07 16:07 ET
CareDx published news for 2020 q3